BNP Paribas Financial Markets grew its position in Sanofi (NASDAQ:SNY - Free Report) by 67.5% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 121,613 shares of the company's stock after acquiring an additional 49,021 shares during the quarter. BNP Paribas Financial Markets' holdings in Sanofi were worth $5,865,000 at the end of the most recent reporting period.
Other hedge funds have also recently modified their holdings of the company. Invesco Ltd. lifted its holdings in Sanofi by 3.5% in the fourth quarter. Invesco Ltd. now owns 12,059,283 shares of the company's stock valued at $581,619,000 after acquiring an additional 408,752 shares during the period. Price T Rowe Associates Inc. MD increased its position in shares of Sanofi by 88.5% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 10,843,682 shares of the company's stock valued at $522,991,000 after buying an additional 5,091,304 shares in the last quarter. Boston Partners increased its position in shares of Sanofi by 86.4% in the fourth quarter. Boston Partners now owns 5,396,531 shares of the company's stock valued at $260,607,000 after buying an additional 2,501,073 shares in the last quarter. Franklin Resources Inc. increased its position in shares of Sanofi by 10.8% in the fourth quarter. Franklin Resources Inc. now owns 3,776,982 shares of the company's stock valued at $182,164,000 after buying an additional 369,530 shares in the last quarter. Finally, Magnetar Financial LLC increased its position in shares of Sanofi by 104.3% in the fourth quarter. Magnetar Financial LLC now owns 3,340,317 shares of the company's stock valued at $161,103,000 after buying an additional 1,705,148 shares in the last quarter. 14.04% of the stock is owned by institutional investors and hedge funds.
Wall Street Analyst Weigh In
A number of research analysts have recently weighed in on the company. Sanford C. Bernstein upgraded Sanofi to a "strong-buy" rating in a research report on Thursday, January 30th. BNP Paribas began coverage on Sanofi in a research report on Tuesday, April 15th. They set an "outperform" rating and a $65.00 price objective for the company. The Goldman Sachs Group began coverage on Sanofi in a research report on Friday, March 21st. They set a "neutral" rating and a $65.00 price objective for the company. Deutsche Bank Aktiengesellschaft upgraded Sanofi from a "sell" rating to a "hold" rating in a research report on Thursday, January 30th. Finally, Hsbc Global Res upgraded Sanofi to a "strong-buy" rating in a research report on Monday, April 28th. Three analysts have rated the stock with a hold rating, two have given a buy rating and three have assigned a strong buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Buy" and a consensus target price of $63.33.
Check Out Our Latest Research Report on SNY
Sanofi Trading Up 1.6%
Shares of NASDAQ SNY traded up $0.82 during midday trading on Friday, hitting $51.68. The stock had a trading volume of 2,724,204 shares, compared to its average volume of 2,380,900. The company has a market capitalization of $130.56 billion, a price-to-earnings ratio of 20.76, a PEG ratio of 1.01 and a beta of 0.55. Sanofi has a 1-year low of $45.80 and a 1-year high of $60.12. The company has a quick ratio of 1.14, a current ratio of 1.46 and a debt-to-equity ratio of 0.15. The company has a fifty day moving average price of $53.36 and a 200 day moving average price of $51.88.
Sanofi (NASDAQ:SNY - Get Free Report) last released its quarterly earnings data on Thursday, April 24th. The company reported $0.94 earnings per share for the quarter, beating the consensus estimate of $0.90 by $0.04. The business had revenue of $10.41 billion for the quarter, compared to analyst estimates of $9.79 billion. Sanofi had a return on equity of 25.61% and a net margin of 12.77%. The company's revenue was down 11.0% compared to the same quarter last year. During the same period in the previous year, the company posted $1.78 EPS. On average, analysts predict that Sanofi will post 4.36 earnings per share for the current year.
Sanofi Increases Dividend
The company also recently disclosed an annual dividend, which will be paid on Thursday, June 12th. Stockholders of record on Friday, May 9th will be paid a $2.0369 dividend. This is a positive change from Sanofi's previous annual dividend of $1.48. This represents a dividend yield of 3.1%. The ex-dividend date of this dividend is Friday, May 9th. Sanofi's payout ratio is currently 57.14%.
Sanofi Profile
(
Free Report)
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.
See Also
Before you consider Sanofi, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sanofi wasn't on the list.
While Sanofi currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
